Protocol Ledger

NCT03447249 · Phase III · COMPLETED

A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Interventional Phase III clinical trial protocol NCT03447249 sponsored by Vertex Pharmaceuticals in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-03-07 Enrollment: 385 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03447249
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)385 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03447249
Protocol FieldVerified Registry Value
NCT IdentifierNCT03447249
Consolidated Lead SponsorVertex Pharmaceuticals
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment385 participants (ACTUAL)
Registered Start Date2018-03-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Vertex Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI